8-K
filed July 5, 2022, 7:59 PM ET
ticker ELOX
CIK 0001035354
leadership
confidence high
sentiment neutral
materiality 0.65
Eloxx Pharmaceuticals appoints Lindsay Androski to board; five directors resign, board shrinks from nine to five
Eloxx Pharmaceuticals, Inc.
- Five directors (Gadi Veinrib, Ran Nussbaum, Zafrira Avnur, Rajesh Parekh, Jasbir Seehra) resign effective July 1, 2022.
- Board size reduced from nine to five directors; Alan Walts and Tomer Kariv appointed as committee chairs.
- Lindsay Androski appointed to fill vacancy, joining Audit and Compensation Committees.
- Androski is President/CEO of Roivant Social Ventures and was part of founding team at Roivant Sciences.
- Company states resignations not due to any disagreement; aims for a 'nimble and focused' board.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Gadi Veinrib resigned as Director at Eloxx Pharmaceuticals, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
On June 30, 2022, each of Zafrira Avnur, Rajesh Parekh and Gadi Veinrib notified the Board of their respective resignations from the Board and the respective committees of the Board on which they serve.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Zafrira Avnur resigned as Director at Eloxx Pharmaceuticals, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
On June 30, 2022, each of Zafrira Avnur, Rajesh Parekh and Gadi Veinrib notified the Board of their respective resignations from the Board and the respective committees of the Board on which they serve.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Rajesh Parekh resigned as Director at Eloxx Pharmaceuticals, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
On June 30, 2022, each of Zafrira Avnur, Rajesh Parekh and Gadi Veinrib notified the Board of their respective resignations from the Board and the respective committees of the Board on which they serve.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Jasbir Seehra resigned as Director at Eloxx Pharmaceuticals, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
On June 28, 2022, each of Ran Nussbaum and Jasbir Seehra notified the Board of Directors (the “Board”) of Eloxx Pharmaceuticals, Inc. (the “Company”) of their respective resignations from the Board and the respective committees of the Board on which they serve.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Ran Nussbaum resigned as Director at Eloxx Pharmaceuticals, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
On June 28, 2022, each of Ran Nussbaum and Jasbir Seehra notified the Board of Directors (the “Board”) of Eloxx Pharmaceuticals, Inc. (the “Company”) of their respective resignations from the Board and the respective committees of the Board on which they serve.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Lindsay Androski was appointed as Director at Eloxx Pharmaceuticals, Inc..
- Action
- appointed
- Role
- Director
Exact text from the filing
On June 30, 2022, the Board appointed Lindsay Androski to serve as a director on the Company’s Board to fill the remaining vacancy and as a member of the Board’s Audit Committee and Compensation Committee, in each case, effective as of the Effective Time.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.